You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Mallinckrodt
Dow
Express Scripts
Merck

Last Updated: October 31, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,925,265

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,925,265
Title:Methods of treating or preventing stent thrombosis
Abstract: The present invention is directed to the following: methods of treating or preventing stent thrombosis using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; methods of reducing mortality in a subject undergoing stent implantation using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; medicaments comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation; pharmaceutical compositions comprising cangrelor and bivalirudin; and methods of preparing a medicament comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation.
Inventor(s): Arculus-Meanwell; Clive Arthur (Bernardsville, NJ), Skerjanec; Simona (Basel, CH)
Assignee: Chiesi Farmaceutici S.p.A. (Parma, IT)
Application Number:12/943,717
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,925,265
Patent Claims: 1. A method of treating stent thrombosis in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising cangrelor, thereby treating stent thrombosis in a subject, wherein the pharmaceutical composition is administered intravenously as bolus in a dose of about 30 .mu.g/kg cangrelor followed by a continuous infusion and wherein stent thrombosis is induced by implantation of a bare metal stent or a drug eluting stent into the subject.

2. The method of claim 1, wherein the pharmaceutical composition further comprises bivalirudin.

3. A method of reducing mortality in a subject undergoing stent implantation, comprising parenterally administering to the subject an effective amount of a pharmaceutical composition comprising cangrelor and an effective amount of a pharmaceutical composition comprising bivalirudin, thereby reducing mortality in a subject undergoing stent implantation, wherein the pharmaceutical composition comprising cangrelor is administered intravenously as bolus in a dose of about 30 .mu.g/kg cangrelor followed by a continuous infusion, and wherein a likelihood of mortality is reduced in comparison to a likelihood of mortality in a subject not receiving the pharmaceutical composition comprising cangrelor that is administered intravenously as bolus in a dose of about 30 .mu.g/kg cangrelor followed by a continuous infusion.

4. The method of claim 3, wherein the cangrelor and the bivalirudin are in the same pharmaceutical composition.

5. A method of treating or preventing myocardial infarction in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising cangrelor, thereby treating or preventing myocardial infarction in a subject, wherein the pharmaceutical composition is administered intravenously as bolus in a dose of about 30 .mu.g/kg cangrelor followed by a continuous infusion.

6. The method of claim 5, wherein the pharmaceutical composition further comprises bivalirudin.

7. The method of claim 1, wherein stent thrombosis is intraprocedural stent thrombosis, acute stent thrombosis, sub-acute stent thrombosis, late stent thrombosis or very late stent thrombosis.

8. The method of claim 3, wherein stent implantation is implantation of a bare-metal stent or a drug-eluting stent into the subject.

9. The method of claim 3, wherein stent implantation is during percutaneous coronary intervention (PCI).

10. The method of claim 3, wherein the pharmaceutical composition comprising cangrelor is administered before stent implantation, during stent implantation, or a combination thereof.

11. The method of claim 3, wherein the pharmaceutical composition comprising bivalirudin is administered before stent implantation, during stent implantation, or a combination thereof.

12. The method of claim 3, wherein the pharmaceutical composition comprising cangrelor is administered to the subject prior to stent implantation and said administration is continued during the period of stent implantation.

13. The methods of claim 3 or 4, wherein mortality is reduced over a period of about one year after stent implantation.

14. The method of claim 1, 3, or 5, wherein the pharmaceutical composition comprises about 1 mg/mL cangrelor.

15. The method of claim 1, 3, or 5, wherein the pharmaceutical composition comprises about 5 mg/mL cangrelor.

16. The method of claim 2, 4, or 6, wherein the pharmaceutical composition comprises about 1 mg/mL cangrelor and about 1 mg/mL bivalirudin.

17. The method of claim 2, 4, or 6, wherein the pharmaceutical composition comprises about 1 mg/mL cangrelor and about 5 mg/mL bivalirudin.

18. The method of claim 2, 4, or 6, wherein the pharmaceutical composition comprises about 5 mg/mL cangrelor and about 1 mg/mL bivalirudin.

19. The method of claim 2, 4, or 6, wherein the pharmaceutical composition comprises about 5 mg/mL cangrelor and about 5 mg/mL bivalirudin.

20. The method of claim 12, wherein the continuous intravenous infusion is administered at about 4 .mu.g/kg/min cangrelor.

21. The method of claim 3, wherein the pharmaceutical composition comprising bivalirudin is administered to the subject as an intravenous bolus, as a continuous intravenous infusion, or as an intravenous bolus followed by a continuous intravenous infusion prior to stent implantation and said administration is continued during the period of stent implantation.

22. The method of claim 21, wherein the intravenous bolus is administered in a dose of about 0.75 mg/kg bivalirudin.

23. The method of claim 21, wherein the continuous intravenous infusion is administered at about 1.75 mg/kg/h bivalirudin.

24. The method of claim 3, wherein the pharmaceutical composition comprising cangrelor and the pharmaceutical composition comprising bivalirudin are administered concurrently.

25. The method of claim 9, wherein the pharmaceutical composition comprising bivalirudin is administered periprocedurally to PCI.

26. A method of preventing stent thrombosis in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising cangrelor, thereby preventing stent thrombosis in a subject, wherein the pharmaceutical composition is administered intravenously as bolus in a dose of about 30 .mu.g/kg cangrelor followed by a continuous infusion, wherein preventing stent thrombosis is prevention during percutaneous coronary intervention or other vascular stent implantation.

27. The method of claim 3, wherein the pharmaceutical composition comprising cangrelor is administered after stent implantation.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Harvard Business School
Dow
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.